This study plans to enroll 4-20 patients to assess the safety of C-CAR031. Subjects who meet the eligibility criteria will receive a single dose of C-CAR031 injection, and will be followed up post treatment for safety monitoring. The follow up period will last 12 months.
A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.